Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

Multiple surgeries for glaucoma increased the risk of corneal edema in these patients, making lower-risk treatment ...